Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Canaani, Jonathan  [Clear All Filters]
2022
Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, Nagler A, Shimoni A. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/ myelodysplastic syndromes after a first transplantation. Haematologica. 2022.
2021
Danylesko I, Canaani J, Shimoni A, Fein J, Shem-Tov N, Yerushalmi R, Shouval R, Nagler A. Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Acta Haematol. 2021:1-7.
Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.
Apel A, Moshe Y, Ofran Y, Gural A, Wolach O, Ganzel C, Canaani J, Zektser M, Duek A, Stemer G, et al. Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol. 2021.
2019
Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, et al. OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. Biol Blood Marrow Transplant. 2019.
2018
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R-M, Niederwieser D, Volin L, Markiewicz M, Arnold R, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. An ALWP/EBMT analysis. J Intern Med. 2018.
2016
Canaani J, Luger SM. Revisiting maintenance therapy in acute myeloid leukemia with novel agents. Curr Opin Hematol. 2016.